Holen Sie sich die Stockscreener-App
45.76
1.37%
0.62
Vorhandelsmarkt:
45.89
0.13
+0.28%
Schlusskurs vom Vortag:
$45.14
Offen:
$45.04
24-Stunden-Volumen:
573.78K
Relative Volume:
0.66
Marktkapitalisierung:
$2.98B
Einnahmen:
$58.89M
Nettoeinkommen (Verlust:
$-240.88M
KGV:
-14.76
EPS:
-3.1
Netto-Cashflow:
$-239.96M
1W Leistung:
+1.89%
1M Leistung:
-0.24%
6M Leistung:
+3.69%
1J Leistung:
+7.75%
1-Tages-Spanne:
$44.11
$45.98
1-Wochen-Bereich:
$44.11
$47.30
52-Wochen-Spanne:
$19.45
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Vergleichen Sie KYMR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
45.76 | 3.15B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
What analysts say about Kymera Therapeutics Inc. stockHigh-profit stock alerts - jammulinksnews.com
Is Kymera Therapeutics Inc. a good long term investmentConsistent wealth multiplication - Autocar Professional
Kymera Therapeutics Inc. Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
What drives Kymera Therapeutics Inc. stock priceOutstanding trading profits - printweek.in
What makes Kymera Therapeutics Inc. stock price move sharplyAlpha Stock Ideas - beatles.ru
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? - Yahoo Finance
Goldman Sachs Initiates Coverage on Kymera Therapeutics as Early-Stage Biotech with Potential Upside of 33.75% - AInvest
How Kymera Therapeutics Inc. stock performs during market volatilityFree Risk Assessment Services - Newser
Forecasting the Future: Targeted Protein Degradation - openPR.com
Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating - Insider Monkey
Kymera Therapeutics shares fall 1.26% intraday amid Gilead Sciences' clinical hold on HIV treatment trials. - AInvest
Kymera Therapeutics stock price target lowered to $65 at Brookline Capital - Investing.com Canada
(KYMR) Investment Analysis - news.stocktradersdaily.com
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion - Investing.com Canada
Kymera Therapeutics (KYMR) director group buys $13.9 million in stock By Investing.com - Investing.com South Africa
Kymera Therapeutics: Baker Bros acquire $28.8m in shares By Investing.com - Investing.com South Africa
Kymera Therapeutics: Baker Bros acquire $28.8m in shares - Investing.com
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer - MSN
Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus
Oppenheimer Adjusts Price Target for Kymera Therapeutics (KYMR) - GuruFocus
KYMR: Key Insights on Recent Developments | KYMR Stock News - GuruFocus
Kymera Therapeutics Announces Pricing of $250 Million Public Offering - The Manila Times
Gilead and Kymera in pact to develop cancer drugs - MSN
Kymera Therapeutics (KYMR) Target Price Lowered by Wells Fargo | KYMR Stock News - GuruFocus
KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update - TradingView
Kymera Therapeutics launches $250 million public stock offering - Investing.com
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - PharmaLive
Gilead (GILD) Enters Agreement with Kymera to Enhance Cancer Tre - GuruFocus
Kymera Therapeutics (KYMR) Advances IRAK4 Partnership with Sanofi | KYMR Stock News - GuruFocus
Kymera signs $750m cancer deal with Gilead as Sanofi opts in - pharmaphorum
Gilead (GILD) Enters Agreement with Kymera for Novel Cancer Trea - GuruFocus
When (KYMR) Moves Investors should Listen - news.stocktradersdaily.com
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com
Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):